Customer Concentration

9 Months Ended

Sep. 30, 2017

Customer Concentration [Abstract]

Concentration Risk Disclosure [Text Block]

5. Concentration of Credit Risk

Customer Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of the Company’s total revenues, was as follows:

		Three Months Ended September 30,				Nine Months Ended September 30,
Licensee	Product Name	2017		2016		2017		2016
Genentech	Avastin	—	%	—	%	—	%	22	%
	Herceptin	—	%	—	%	—	%	22	%
Biogen	Tysabri®	2	%	28	%	13	%	24	%
Depomed	Glumetza, Janumet XR, Jentadueto XR and Invokamet XR	50	%	18	%	50	%	N/A
N/A	Tekturna, Tekturna HCT, Rasilez and Rasilez HCT	24	%	26	%	17	%	8	%

__________________

N/A = Not applicable